Literature DB >> 12009962

A simple two-step approach for introducing a protected diaminedithiol chelator during solid-phase assembly of peptides.

Jean Gariépy1, Sandrine Rémy, Xiuguo Zhang, James R Ballinger, Eleonora Bolewska-Pedyczak, Michael Rauth, Stuart K Bisland.   

Abstract

A simple synthetic strategy is described to incorporate a protected diaminedithiol (N(2)S(2)) chelator during Fmoc solid-phase synthesis of short peptides. The resulting constructs could be efficiently labeled with technetium-99m (99mTc). The chelator was assembled at the N-terminus of peptides in a two-step procedure where the deprotected terminal amino group was first reacted with di-Fmoc-diaminopropionic acid (Fmoc-DAP-[Fmoc]-OH). The two protected amino groups were then simultaneously deprotected and subsequently reacted with S-benzoylthiolglycolic acid (TGA) to generate a protected N(2)S(2) chelator. This metal binding site was introduced into di- and tripeptides. Each peptide construct was composed of a C-terminal lysine residue and an N-terminal diaminopropionic moiety modified to create the chelator site. The epsilon-amino group at the C-terminal lysine was further derivatized with a nitroimidazole group to facilitate cellular retention. The resulting constructs were then cleaved from the resin support, purified, and labeled with [99mTc]pertechnetate. Six constructs were prepared differing by a single amino acid inserted between the diaminopropionic acid and lysine residues. Optimal labeling yields of >70% were achieved around neutral pH and heating at 75 degrees C for 10 min. Purified 99mTc-labeled constructs were found to accumulate in Chinese hamster ovary (CHO) cells in vitro as a function of charge and hydrophobicity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12009962     DOI: 10.1021/bc0100814

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  2 in total

1.  Development of hypoxia enhanced 111In-labeled Bombesin conjugates: design, synthesis, and in vitro evaluation in PC-3 human prostate cancer.

Authors:  Nilesh K Wagh; Zhengyuan Zhou; Sunny M Ogbomo; Wen Shi; Susan K Brusnahan; Jered C Garrison
Journal:  Bioconjug Chem       Date:  2012-02-16       Impact factor: 4.774

2.  PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog.

Authors:  Mathew L Thakur; Mohan R Aruva; Jean Gariepy; Paul Acton; Satish Rattan; Shyam Prasad; Eric Wickstrom; Abass Alavi
Journal:  J Nucl Med       Date:  2004-08       Impact factor: 10.057

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.